 | Your browser does not display parts of our website correctly. We use the latest technology available to provide you with a high quality experience; please upgrade your browser to its latest version to view the contents properly: |
Stockwinners Market Radar for September 24, 2017 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service |
| FOXA... | Hot Stocks20:04 EDT On The Fly: Top five weekend stock stories - Catch up on the weekend's top five stories with this list compiled by The Fly: 1. The new proposal by Republicans to repeal and replace the Affordable Health Care suffered new setbacks within the party on Sunday, when Senator Ted Cruz expressed his opposition and Senator Susan Collins voiced strong criticism, according to Reuters. Senators John McCain and Rand Paul had previously said they would vote against the "Graham-Cassidy" bill, which Senate Majority Leader Mitch McConnell "intends" to put up for a vote this week, the publication noted. Publicly traded companies in the space include Aetna (AET), Anthem (ANTM), Centene (CNC), Cigna (CI), Health Net (HNT), Humana (HUM), Molina Healthcare (MOH), UnitedHealth (UNH) and WellCare (WCG). 2. This weekend, NFL teams staged a show of solidarity with protesting players by kneeling, linking arms or staying off the field during the national anthem. This comes after President Donald Trump called for owners to fire those who refuse to stand and for fans to boycott NFL games. Following the steps of former San Francisco 49ers quarterback Colin Kaepernick, who sat during the anthem last season to call attention to what he saw as a pattern of racism in the way police treats African-Americans, several NFL players have since "taken one knee" or linked arms during the playing of the national anthem. 3. Gene therapy is rapidly emerging as one of the most exciting areas in biotechnology, and generating new hope for patients with rare and often deadly inherited diseases, Andre Bary wrote in this week's edition of Barron's. The first regulatory approval for replacement gene therapy could come as soon as January, if the FDA gives the go-ahead to Spark Therapeutics (ONCE) for its one-time treatment that targets a rare, inherited retinal condition leading to blindness, he added. Other publicly traded companies developing treatments in this area include AveXis' (AVXS), Regenxbio (RGNX), Audentes Therapeutics (BOLD), and Voyager Therapeutics (VYGR). 4. "Kingsman: The Golden Circle" easily won the weekend in North America, grossing $39M from 4,003 theaters. While the sequel scored one of the best openings for the month of September, it came in somewhat behind expectations. Overseas, Kingsman 2 kicked off with $61M, for a global tally of $100M. The movie was distributed by 20th Century Fox (FOXA) and received a 51% rating on Rotten Tomatoes. 5. Oracle (ORCL), GoPro (GPRO), Xilinx (XLNX), Synopsys (SNPS), and Cadence Design (CDNS) saw positive mentions in Barron's, while Six Flags (SIX), Honda (HMC), and iRobot (IRBT) were mentioned cautiously.
|
| NVCR | Hot Stocks18:27 EDT Combination of Novocure Optune with Temozolomide demonstrates five-year survival - Novocure announced today results from its phase 3 pivotal EF-14 trial adding Optune to temozolomide for the treatment of newly diagnosed glioblastoma, or GBM, including results from health-related quality of life analyses, were presented at the American Society for Radiation Oncology's 2017 Annual Meeting in San Diego. Novocure's EF-14 phase 3 pivotal trial demonstrated "unprecedented" five-year survival results in newly diagnosed GBM. Patients treated with Optune in combination with temozolomide experienced a significant extension of overall survival without added toxicity compared to patients treated with temozolomide alone. The data also showed that Optune-treated patients were able to maintain quality of life for longer compared to patients treated with temozolomide alone. The EF-14 data showed median overall survival was extended by nearly five months for patients who received Optune in combination with temozolomide versus patients who received temozolomide alone. When measured annually for five consecutive years, patients treated with Optune in combination with temozolomide maintained superior rates of survival in newly diagnosed GBM versus patients treated with temozolomide alone. The five-year survival rate was 13% for patients treated with Optune together with temozolomide versus five percent for patients treated with temozolomide alone. The EF-14 data also showed that Optune with temozolomide did not negatively impact health-related quality of life, except for itchy skin. The combination treatment of Optune with temozolomide improved deterioration-free survival of several predefined health-related quality of life scales, compared to treatment with temozolomide alone.
|
| TWX... | Hot Stocks17:10 EDT Box Office Battle: 'Kingsman: The Golden Circle' easily wins weekend - "Kingsman: The Golden Circle" easily won the weekend in North America, grossing $39M from 4,003 theaters. While the sequel scored one of the best openings for the month of September, it came in somewhat behind expectations. Overseas, Kingsman 2 kicked off with $61M, for a global tally of $100M. The movie was distributed by 20th Century Fox (FOXA) and received a 51% rating on Rotten Tomatoes. BOX OFFICE RUNNERS-UP: New Line Cinema and Warner Bros. (TWX) horror movie "It" followed at number 2, with the movie's domestic cume standing at $266.3M. Behind it was Warner Bros.' animated family offering "The Lego Ninjago Movie," which launched to a meek $21.2M from 4,047 locations domestically. Lionsgate's (LGF.A) "American Assassin" followed at number four, with an estimated $6.2M in its second weekend for a domestic total of $26.2M. Rounding out the top five, the romantic comedy distributed by Open Road films "Home Again" earned an estimated $3.3M. Other publicly traded companies in filmmaking include Viacom (VIAB; VIA), Sony (SNE), Comcast (CMCSA), and Walt Disney (DIS).
|
| SAP | Hot Stocks16:11 EDT SAP announces acquisition of Gigya - SAP has announced it has entered into an agreement to acquire Gigya. The latter's platform allows companies to manage customers' profile, preference, opt-in and consent settings, with customers maintaining control of their data at all times. Customers opt in and register via Gigya's registration-as-a-service, which addresses changing geographical privacy issues and manages compliance requirements such as the upcoming General Data Protection Regulation. Gigya currently manages 1.3B customer identities in order to build identity-driven relationships for its enterprise clients. Gigya, an SAP Hybris2 partner since 2013, has customers already using a solution extension from SAP Hybris and Gigya. By way of the acquisition, SAP Hybris intends to become the first organization to offer a cloud-based data platform enabling companies to profile and convert new customers, gather accurate conclusions from disparate consumer engagement sources and collect data for enhanced consumer choices that are in line with regulations. Gigya has more than 300 employees and is headquartered in Mountain View, California. The company's operations will become part of the SAP Hybris business unit for customer engagement and commerce. The transaction is expected to close in the final quarter of 2017, subject to regulatory approval. Terms of the transaction are not disclosed.
|
| TATT... | Hot Stocks16:03 EDT TAT Technologies awarded APU MRO contract for fleet of Boeing, Airbus - TAT Technologies (TATT), through its subsidiary Piedmont Aviation Component Services, has been awarded a five-year Auxiliary Power Unit, or APU, Maintenance Support for a large fleet of Boeing (BA) and Airbus (EADSY) aircrafts, estimated at up to $40M in revenue. Maintenance work will be done at TAT's APU services facility in Greensboro, NC, starting Q4 2017.
|
